Matches in Wikidata for { <http://www.wikidata.org/entity/Q65369925> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q65369925 description "clinical trial" @default.
- Q65369925 description "ensayu clínicu" @default.
- Q65369925 description "klinisch onderzoek" @default.
- Q65369925 description "клінічне випробування" @default.
- Q65369925 name "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 name "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 type Item @default.
- Q65369925 label "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 label "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 prefLabel "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 prefLabel "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery" @default.
- Q65369925 P1132 Q65369925-394DB05A-56C3-425C-B3A6-266A58E96E54 @default.
- Q65369925 P1476 Q65369925-4E9EE026-16FF-47A0-9094-46B435D9A12F @default.
- Q65369925 P17 Q65369925-60888442-310D-4418-8956-C85A513ADA9B @default.
- Q65369925 P2899 Q65369925-08FB65B8-8394-4F51-B52D-66BC6766F511 @default.
- Q65369925 P3098 Q65369925-4612F05E-0BE2-47F8-B1EF-8ABD168E9BCA @default.
- Q65369925 P31 Q65369925-6AB8443C-E730-4D24-BBEB-A37D78D5557B @default.
- Q65369925 P4844 Q65369925-07219591-4270-4A6F-99A2-A31A7B1BC6AA @default.
- Q65369925 P4844 Q65369925-0E3E1E41-98F5-4151-8611-741F65738CE5 @default.
- Q65369925 P4844 Q65369925-BD77C69B-0592-4D70-8BF0-FE5B49223A42 @default.
- Q65369925 P580 Q65369925-5ED0F0F5-A47C-48EA-9AF4-5476FD00FFC3 @default.
- Q65369925 P582 Q65369925-7414DCFC-1E7F-4E82-9710-3E2E0E64B991 @default.
- Q65369925 P6099 Q65369925-6007337A-3EC0-4158-9968-EBC9AAC2DC4A @default.
- Q65369925 P8363 Q65369925-E3E7AF58-9E5E-4F7F-95DF-6397EF0150AD @default.
- Q65369925 P1132 "+33" @default.
- Q65369925 P1476 "A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies" @default.
- Q65369925 P17 Q30 @default.
- Q65369925 P2899 "+18" @default.
- Q65369925 P3098 "NCT01787500" @default.
- Q65369925 P31 Q30612 @default.
- Q65369925 P4844 Q412197 @default.
- Q65369925 P4844 Q423111 @default.
- Q65369925 P4844 Q50429626 @default.
- Q65369925 P580 "2013-02-15T00:00:00Z" @default.
- Q65369925 P582 "2024-03-31T00:00:00Z" @default.
- Q65369925 P6099 Q5452194 @default.
- Q65369925 P8363 Q78089383 @default.